Last $1.82 USD
Change Today +0.04 / 2.25%
Volume 87.1K
GNVC On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 1:19 PM 10/30/14 All times are local (Market data is delayed by at least 15 minutes).

genvec inc (GNVC) Snapshot

Open
$1.81
Previous Close
$1.78
Day High
$1.84
Day Low
$1.77
52 Week High
01/23/14 - $4.25
52 Week Low
11/13/13 - $1.19
Market Cap
31.4M
Average Volume 10 Days
27.6K
EPS TTM
$-0.47
Shares Outstanding
17.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENVEC INC (GNVC)

Related News

No related news articles were found.

genvec inc (GNVC) Related Businessweek News

No Related Businessweek News Found

genvec inc (GNVC) Details

GenVec, Inc. operates as a biopharmaceutical company that uses differentiated and proprietary technologies to create therapeutics and vaccines. The company develops its product candidates through collaborations with various companies and organizations, including Novartis AG, Merial Limited, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of various human and animal health concerns. Its development programs address various therapeutic areas, such as hearing loss and balance disorders; and vaccines against infectious diseases, including respiratory syncytial virus, herpes simplex virus, dengue fever, and malaria. The company is also involved in developing vaccines against foot-and-mouth disease in the area of animal health. GenVec, Inc. was founded in 1992 and is based in Gaithersburg, Maryland.

11 Employees
Last Reported Date: 03/28/14
Founded in 1992

genvec inc (GNVC) Top Compensated Officers

Chief Executive Officer, President, Chief Fin...
Total Annual Compensation: $316.3K
Senior Vice President of Development
Total Annual Compensation: $278.1K
Chief Scientific Officer
Total Annual Compensation: $310.7K
Compensation as of Fiscal Year 2013.

genvec inc (GNVC) Key Developments

GenVec, Inc. Announces Retirement of Zola P. Horovitz from its Board of Directors, Effective on October 24, 2014

GenVec, Inc. announced the retirement of Zola P. Horovitz, Ph.D., from its board of directors effective on October 24, 2014. Dr. Horovitz joined the GenVec board in August 2003, and served as its chairman from June 2006 to November 2013. During his tenure, he also served on the Nominating and Corporate Governance and Audit Committees of the board.

GenVec, Inc. Reports Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2014

GenVec, Inc. reported unaudited financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net loss of $1.7 million or $0.10 per basic and diluted share on revenues of $0.1 million as compared to a net loss of $3.1 million or $0.24 per basic and diluted share on revenues of $0.7 million in the same period in the prior year. The decrease in revenue for the three months period ended June 30, 2014 is primarily due to a decrease of $0.2 million associated with its Foot and Mouth Disease (FMD) program, $0.1 million associated with its hearing loss and balance disorders program and $0.3 million due to reduced work scope and grant work performed for its NIH programs and malaria programs. Loss from operations was $1,676,000 compared to $3,131,000 last year. For the six months the company reported a net loss of $2.6 million or $0.17 per basic and diluted share on revenues of $2.3 million as compared to a net loss of $6.2 million or $0.48 per basic and diluted share on revenues of $2.0 million in the same period in the prior year. The increase in revenue for the six months ended June 30, 2014 is primarily due to an increase of $1.5 million associated with its hearing loss and balance disorders program as a result of the achievement of the third milestone under its Agreement with Novartis. Loss from operations was $2,640,000 compared to $6,185,000 last year.

GenVec, Inc. Announces Auditor Changes

On June 11, 2014, the Audit Committee of the Board of Directors of GenVec, Inc. dismissed KPMG LLP as the company's independent registered public accounting firm, effective immediately. On June 11, 2014, the Audit Committee approved the engagement of Stegman & Company as its independent registered public accounting firm for the fiscal year ending December 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNVC:US $1.82 USD +0.04

GNVC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $3.14 USD +0.0204
Eurocine Vaccines AB kr12.50 SEK +0.30
Genocea Biosciences Inc $9.05 USD +0.05
Vical Inc $1.15 USD -0.065
ZIOPHARM Oncology Inc $3.09 USD +0.075
View Industry Companies
 

Industry Analysis

GNVC

Industry Average

Valuation GNVC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.4x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENVEC INC, please visit www.genvec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.